LEMONADE INC (LMND)

US52567D1072 - Common Stock

38.56  +0.61 (+1.61%)

After market: 38.56 0 (0%)

Fundamental Rating

2

Taking everything into account, LMND scores 2 out of 10 in our fundamental rating. LMND was compared to 141 industry peers in the Insurance industry. LMND has a bad profitability rating. Also its financial health evaluation is rather negative. LMND shows excellent growth, but is valued quite expensive already.



0

1. Profitability

1.1 Basic Checks

LMND had negative earnings in the past year.
In the past year LMND has reported a negative cash flow from operations.
In the past 5 years LMND always reported negative net income.
In the past 5 years LMND always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of LMND (-11.77%) is worse than 96.40% of its industry peers.
LMND's Return On Equity of -36.19% is on the low side compared to the rest of the industry. LMND is outperformed by 94.24% of its industry peers.
Industry RankSector Rank
ROA -11.77%
ROE -36.19%
ROIC N/A
ROA(3y)-16.03%
ROA(5y)-17.81%
ROE(3y)-30.73%
ROE(5y)-30.25%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LMND does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

2

2. Health

2.1 Basic Checks

LMND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LMND has more shares outstanding
LMND has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LMND is higher compared to a year ago.

2.2 Solvency

A Debt/Equity ratio of 0.11 indicates that LMND is not too dependend on debt financing.
LMND has a Debt to Equity ratio of 0.11. This is amongst the best in the industry. LMND outperforms 80.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC9.22%

2.3 Liquidity

A Current Ratio of 0.14 indicates that LMND may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.14, LMND is in the better half of the industry, outperforming 69.06% of the companies in the same industry.
LMND has a Quick Ratio of 0.14. This is a bad value and indicates that LMND is not financially healthy enough and could expect problems in meeting its short term obligations.
LMND has a Quick ratio of 0.14. This is in the better half of the industry: LMND outperforms 69.06% of its industry peers.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.50% over the past year.
LMND shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.47%.
LMND shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 80.39% yearly.
EPS 1Y (TTM)18.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.95%
Revenue 1Y (TTM)22.47%
Revenue growth 3Y65.74%
Revenue growth 5Y80.39%
Sales Q2Q%19.3%

3.2 Future

Based on estimates for the next years, LMND will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.08% on average per year.
Based on estimates for the next years, LMND will show a very strong growth in Revenue. The Revenue will grow by 24.66% on average per year.
EPS Next Y9.23%
EPS Next 2Y10.38%
EPS Next 3Y13.08%
EPS Next 5YN/A
Revenue Next Year22.45%
Revenue Next 2Y24.55%
Revenue Next 3Y26.57%
Revenue Next 5Y24.66%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LMND. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LMND. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

LMND's earnings are expected to grow with 13.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.38%
EPS Next 3Y13.08%

0

5. Dividend

5.1 Amount

LMND does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

LEMONADE INC

NYSE:LMND (1/6/2025, 4:37:37 PM)

After market: 38.56 0 (0%)

38.56

+0.61 (+1.61%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)N/A N/A
Inst Owners42.5%
Inst Owner Change0%
Ins Owners7.64%
Ins Owner Change-8.5%
Market Cap2.75B
Analysts49.33
Price Target31.91 (-17.25%)
Short Float %29.61%
Short Ratio5.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.43%
Min EPS beat(2)9.28%
Max EPS beat(2)9.58%
EPS beat(4)4
Avg EPS beat(4)15.34%
Min EPS beat(4)9.28%
Max EPS beat(4)25.12%
EPS beat(8)8
Avg EPS beat(8)14.87%
EPS beat(12)11
Avg EPS beat(12)13.23%
EPS beat(16)15
Avg EPS beat(16)11.28%
Revenue beat(2)1
Avg Revenue beat(2)0.95%
Min Revenue beat(2)-1.78%
Max Revenue beat(2)3.68%
Revenue beat(4)3
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-1.78%
Max Revenue beat(4)3.68%
Revenue beat(8)7
Avg Revenue beat(8)4.32%
Revenue beat(12)11
Avg Revenue beat(12)4.34%
Revenue beat(16)15
Avg Revenue beat(16)4.37%
PT rev (1m)25.14%
PT rev (3m)58.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.42%
EPS NY rev (1m)0.18%
EPS NY rev (3m)0.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.58
P/FCF N/A
P/OCF N/A
P/B 4.64
P/tB 4.93
EV/EBITDA N/A
EPS(TTM)-3.04
EYN/A
EPS(NY)-2.67
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS6.91
BVpS8.31
TBVpS7.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.77%
ROE -36.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.03%
ROA(5y)-17.81%
ROE(3y)-30.73%
ROE(5y)-30.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.79%
Cap/Sales 1.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z N/A
F-Score4
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)127.61%
Cap/Depr(5y)238.33%
Cap/Sales(3y)4.47%
Cap/Sales(5y)4.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.95%
EPS Next Y9.23%
EPS Next 2Y10.38%
EPS Next 3Y13.08%
EPS Next 5YN/A
Revenue 1Y (TTM)22.47%
Revenue growth 3Y65.74%
Revenue growth 5Y80.39%
Sales Q2Q%19.3%
Revenue Next Year22.45%
Revenue Next 2Y24.55%
Revenue Next 3Y26.57%
Revenue Next 5Y24.66%
EBIT growth 1Y20.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.71%
EBIT Next 3Y20.69%
EBIT Next 5Y23.13%
FCF growth 1Y74.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.59%
OCF growth 3YN/A
OCF growth 5YN/A